MedTrace Logo

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

NCT03045770 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-02-07

No results posted yet for this study

Summary

The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.

Conditions

  • Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Interventions

DRUG

Fluorouracil

Fluorouracil was used as first line treatment with AGC.

DRUG

Oxaliplatin

Oxaliplatin was used as first line treatment with AGC.

DRUG

Irinotecan

Irinotecan was used as first line treatment with AGC.

DRUG

Paclitaxel

Paclitaxel was used as first line treatment with AGC.

DRUG

calcium levofolinate

Calcium levofolinate was used as first line treatment with AGC.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Jianwei Yang · Fujian Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-10
Primary Completion
2019-12-30
Completion
2019-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03045770 on ClinicalTrials.gov